NasdaqCM:OPRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

OptimizeRx Corporation operates as a digital health company that facilitates communication at point-of-care among various stakeholders in healthcare.


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has OptimizeRx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OPRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.8%

OPRX

6.4%

US Healthcare Services

2.5%

US Market


1 Year Return

4.0%

OPRX

53.3%

US Healthcare Services

15.9%

US Market

Return vs Industry: OPRX underperformed the US Healthcare Services industry which returned 50.2% over the past year.

Return vs Market: OPRX underperformed the US Market which returned 14.9% over the past year.


Shareholder returns

OPRXIndustryMarket
7 Day3.8%6.4%2.5%
30 Day12.2%12.4%5.8%
90 Day41.7%35.4%18.2%
1 Year4.0%4.0%53.8%53.3%18.4%15.9%
3 Year311.3%311.3%115.7%114.4%39.9%30.9%
5 Year453.0%453.0%152.4%150.1%72.9%54.2%

Price Volatility Vs. Market

How volatile is OptimizeRx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OptimizeRx undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OPRX ($14.93) is trading below our estimate of fair value ($77.5)

Significantly Below Fair Value: OPRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OPRX is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.

PE vs Market: OPRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OPRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OPRX is good value based on its PB Ratio (5x) compared to the US Healthcare Services industry average (5.4x).


Next Steps

Future Growth

How is OptimizeRx forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

81.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OPRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OPRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OPRX's revenue (24.8% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: OPRX's revenue (24.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OPRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has OptimizeRx performed over the past 5 years?

-20.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OPRX is currently unprofitable.

Growing Profit Margin: OPRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OPRX is unprofitable, and losses have increased over the past 5 years at a rate of 20.4% per year.

Accelerating Growth: Unable to compare OPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (9.9%).


Return on Equity

High ROE: OPRX has a negative Return on Equity (-12.27%), as it is currently unprofitable.


Next Steps

Financial Health

How is OptimizeRx's financial position?


Financial Position Analysis

Short Term Liabilities: OPRX's short term assets ($27.3M) exceed its short term liabilities ($9.5M).

Long Term Liabilities: OPRX's short term assets ($27.3M) exceed its long term liabilities ($3.1M).


Debt to Equity History and Analysis

Debt Level: OPRX is debt free.

Reducing Debt: OPRX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OPRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OPRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is OptimizeRx current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OPRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OPRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OPRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Will Febbo (51 yo)

4.5yrs

Tenure

US$833,990

Compensation

Mr. William J. Febbo, Will, serves as the Independent Director of Modular Medical, Inc. since January 23, 2020. He has been the Chief Executive Officer and Director of OptimizeRx Corp since February 22, 20 ...


CEO Compensation Analysis

Compensation vs Market: Will's total compensation ($USD833.99K) is below average for companies of similar size in the US market ($USD1.33M).

Compensation vs Earnings: Will's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
William Febbo
CEO & Director4.5yrsUS$833.99k1.57%
$ 3.3m
Miriam Paramore
President3yrsUS$462.35k0.16%
$ 340.7k
Douglas Baker
Chief Financial Officer6.25yrsUS$449.53k0.62%
$ 1.3m
Stephen Silvestro
Chief Commercial Officer1.33yrsUS$1.21mno data
Todd Inman
Chief Technology Officer0.42yrno datano data
Terence Hamilton
Senior Vice President of Pharma0.42yrUS$511.63k0.97%
$ 2.0m
Srdjan Loncar
Head of Patient Engagement Solutions0.42yrno datano data
Rebecca Whitney
Senior Vice President of Commercial Operations0.83yrno datano data
Heather Favazza
Controller1.83yrsno datano data
James Brooks
Consultant3.58yrsUS$420.99kno data

1.6yrs

Average Tenure

53yo

Average Age

Experienced Management: OPRX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
William Febbo
CEO & Director4.5yrsUS$833.99k1.57%
$ 3.3m
Patrick Spangler
Independent Director2.42yrsUS$145.35k0.13%
$ 274.6k
Gus Halas
Independent Chairman3.17yrsUS$155.35k0.42%
$ 875.8k
Gregory Wasson
Director0.083yrno datano data
Ellen Vos
Independent Director4.92yrsUS$144.85k0.20%
$ 423.9k
Jack Pinney
Head of Medical Advisory Board2.42yrsUS$112.91kno data
James Lang
Independent Director3.58yrsUS$141.85k0.20%
$ 420.7k

2.8yrs

Average Tenure

63yo

Average Age

Experienced Board: OPRX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.


Top Shareholders

Company Information

OptimizeRx Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OptimizeRx Corporation
  • Ticker: OPRX
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$207.251m
  • Shares outstanding: 14.65m
  • Website: https://www.optimizerx.com

Number of Employees


Location

  • OptimizeRx Corporation
  • 400 Water Street
  • Suite 200
  • Rochester
  • Michigan
  • 48307
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OPRXNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJun 2005

Biography

OptimizeRx Corporation operates as a digital health company that facilitates communication at point-of-care among various stakeholders in healthcare. Its cloud-based solution supports patient adherence to ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/04 00:58
End of Day Share Price2020/08/03 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.